GlassScriptPhysician profile
Omar F Almallah
NPI 1376528364
$5,434.37
in general payments reported to CMS, 2019-2025
31 companies · $818 in 2025
The $818 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754 · 2020: $376 · 2021: $570 · 2022: $792 · 2023: $1,068 · 2024: $1,056 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,701.16 | 2019-2025 | Clareon, Centurion, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $537.10 | 2019-2025 | Tecnis Iol, Veritas Vision System |
| Bausch & Lomb Americas INC. | $444.82 | 2022-2025 | Miebo, Xiidra, Ic-8 Apthera Iol |
| Oyster Point Pharma, INC. | $340.40 | 2022-2025 | Tyrvaya, Ryzumvi |
| Ocular Therapeutix, INC. | $313.51 | 2019-2025 | Dextenza |
| Allergan, INC. | $307.64 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $266.07 | 2019-2025 | Cequa |
| Biotissue Holdings INC. | $180.92 | 2020-2025 | |
| Rxsight INC | $173.82 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Abbvie INC. | $169.44 | 2022-2023 | Xen Glaucoma Treatment System, Lumigan |
| Ivantis, INC | $150.00 | 2019 | |
| New World Medical,INC. | $134.10 | 2022 | |
| Revance Therapeutics, INC. | $108.07 | 2024 | Daxxify |
| Sight Sciences, INC. | $72.63 | 2020-2021 | |
| Rayner Intraocular Lenses Limited | $66.48 | 2022-2025 | Omidria, Rayone Aspheric, Rayone Emv |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $59.85 | 2019-2022 | |
| Dompe US, INC. | $51.04 | 2022-2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $50.33 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $35.99 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $31.18 | 2025 | Syfovre |
| Akorn, INC. | $29.14 | 2020 | |
| Mallinckrodt Hospital Products INC. | $28.27 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.13 | 2019 | |
| Halozyme INC | $26.05 | 2024 | Hylenex Recombinant |
| Tearlab Corp | $23.26 | 2021 | |
| Thea Pharma INC. | $21.40 | 2023 | |
| Glaxosmithkline, LLC. | $20.35 | 2025 | Blenrep |
| Galderma Laboratories, L.P. | $19.39 | 2022 | |
| Omeros Corporation | $18.65 | 2021 | |
| Iridex Corporation | $13.25 | 2019 | |
| Eyevance Pharmaceuticals LLC | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Almallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.